ENDRA Life Sciences Inc. Warrants
NDRAW
NASDAQ Capital Market0.03
USD
+0.02
- -
CIK
0001681682
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
-76.92
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- None
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- DE United States of America
- IPO Date
- Jun 28, 2017
- CIK
- 0001681682
- Similar Companies
- Business
- ENDRA Life Sciences Inc. develops and commercializes advanced imaging technologies focused on the early detection and monitoring of metabolic dysfunction associated liver disease (MASLD) and metabolic dysfunction associated steatohepatitis (MASH). Its core product is the Thermo Acoustic Enhanced UltraSound (TAEUS®) platform, a proprietary technology designed to visualize tissue composition, function, and temperature at the point of care, delivering capabilities comparable to CT and MRI but at a lower cost. The company's initial TAEUS application quantifies liver fat to aid in the early detection and management of liver diseases such as Non-Alcoholic Fatty Liver Disease (NAFLD). ENDRA targets pharmaceutical companies, concierge medical practices, specialized clinics, and primary care providers across North America and Europe. Founded in 2012 and headquartered in Ann Arbor, Michigan, ENDRA operates with a growing patent portfolio of 85 issued patents globally. Recent major developments include the completion of a $14.4 million private placement financing, enabling the company to regain compliance with Nasdaq’s minimum stockholders’ equity requirement and enhance balance sheet flexibility. ENDRA launched a new treasury strategy that involves staking digital assets, specifically its holdings in the HYPE token of the Hyperliquid ecosystem, through partnerships with ARCA Investment Management and Anchorage Digital, creating a non-dilutive value engine to strengthen financial sustainability. The company also announced plans to conduct a 250-subject, multisite clinical trial aimed at FDA De Novo submission for its TAEUS Liver system by year-end 2025. Additionally, ENDRA has significantly reduced operating expenses by 42% in the second quarter, and it continues to advance its next-generation AI-enhanced TAEUS system. A recent management change includes the resignation of Chief Technology Officer Michael Thornton in November 2025. ENDRA’s ongoing strategic focus centers on efficient commercialization of its life-saving liver imaging technology supported by its enhanced financial position.